Technology Assessment Reports (TARs)

Technology Assessment Reports are detailed analyses of new pharmaceuticals. They are used to determine the cost-effectiveness of pharmaceuticals that we are being asked to fund.

Technology Assessment Reports are detailed analyses of new pharmaceuticals. They are used to determine the cost-effectiveness of pharmaceuticals that we are being asked to fund.

We don't publish most of our Technology Assessment Reports because of commercial sensitivity. You can download our published reports on this page.

Published PHARMAC Technology Assessment Reports

Eculizumab (Soliris)

TAR 209 Preliminary economic analysis on eculizumab for paroxysmal nocturnal haemoglobinuria (PNH) May 2013 [PDF, 807 KB]

Nusinersen (Spinraza)

TAR 398 Nusinersen for Spinal Muscular Atrophy February 2020 [PDF, 7.4 MB]

Trastuzumab (Herceptin)

TAR 75a,b Trastuzumab (Herceptin) in HER-2 positive early breast cancer with 9 week regimen CUA [PDF, 566 KB]

TAR 75c Tastuzumab further sensitivity analysis [PDF, 401 KB]

Pembrolizumab

TAR 271a and 271b Pembrolizumab in advanced melanoma [PDF, 7 MB]

Other Technology Assessment Reports

PHARMAC health economic assessment of left atrial appendage occlusion devices (LAAO)

Dabigatran for the prevention of stroke, systemic embolism and reduction of vascular mortality in patient with atrial fibrilation. [PDF, 2.5 MB]

Combined long-acting beta agonist/inhaled corticosteroid devices for asthma (referred to in letter to Journal of Allergy & Clinical Immunology (Metcalfe, Moodie 2003)) [PDF, 76 KB]

Updated statin cost utility analysis [PDF, 120 KB]

Celebrex's relative GI safety is overstated? [PDF, 1.1 MB] A critique and reworking of an industry-sponsored meta-analysis of COX-2 inhibitors (Deeks et al 2002) (sent as a letter to the British Medical Journal, October 2002)